ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Kal Minerals Corp

Kal Minerals Corp (KAL)

0,14
0,00
(0,00%)
Geschlossen 11 Januar 10:00PM

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,14
Gebot
0,135
Fragen
0,40
Volumen
-
0,00 Tagesbereich 0,00
0,14 52-Wochen-Bereich 0,14
Handelsende
0,14
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

KAL Neueste Nachrichten

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders...

American Stock Exchange Accepts Callisto Pharamceuticals' Plan of Compliance and Extension to Regain Compliance with Standards

NEW YORK, Aug. 29 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders...

Hagens Berman Sobol Shapiro: Class Action Lawsuit Filed Against Korean Air Lines

Plaintiff claims suffered damages in Korean Air Lines price fixing conspiracy SEATTLE, Aug. 10 /PRNewswire/ -- Seattle-based law firm Hagens Berman Sobol Shapiro filed a class action lawsuit...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases...

Callisto Reports on Second-Quarter 2007 Milestones

Company Cites Continuing Progress on Clinical and Preclinical Programs NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug...

Callisto Pharmaceuticals Raises $11.2 Million in Series B Preferred Stock Financing

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company primarily focused on the development of new drugs to treat cancer and...

Callisto Pharmaceuticals Opens Additional Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

NEW YORK, June 25 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats...

Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversio

NEW YORK, June 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and...

Callisto Pharmaceuticals Opens Fourth Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

NEW YORK, May 24 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drugs for the treatment of cancer and inflammatory diseases, announced today...

Callisto Pharmaceuticals Announces Article Citing Atiprimod in Major Scientific News Journal

History of Atiprimod Appears in Genetic Engineering & Biotechnology News NEW YORK, May 15 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1000.140.140.1400CS
4000.140.140.1400CS
12000.140.140.1400CS
26000.140.140.1400CS
52000.140.140.1400CS
156000.140.140.1400CS
2600.06750.080.160.0816150.12165007CS

KAL - Frequently Asked Questions (FAQ)

What is the current Kal Minerals share price?
The current share price of Kal Minerals is $ 0,14
What is the 1 year trading range for Kal Minerals share price?
Kal Minerals has traded in the range of $ 0,14 to $ 0,14 during the past year
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SPSSweet Poison Spirits Inc
$ 0,13
(225,00%)
580k
SQXSquatex Energy and Ressources Inc
$ 0,01
(100,00%)
1.000
TGLDTorrent Gold Inc
$ 0,10
(66,67%)
17k
CHGXChitogenX Inc
$ 0,025
(66,67%)
214,5k
HROHero Innovation Group Inc
$ 0,15
(50,00%)
12,53k
EPIC1CM Inc
$ 0,255
(-49,00%)
9,5k
SKURSekur Private Data Ltd
$ 0,02
(-33,33%)
669,03k
RFRRenforth Resources Inc
$ 0,01
(-33,33%)
57k
MYTCMyndTec Inc
$ 0,20
(-33,33%)
1.000
TAATTAAT Global Alternatives Inc
$ 0,17
(-26,09%)
5,5k
PKKPeak Fintech Group Inc
$ 0,05
(-9,09%)
4,96M
QIMCQuebec Innovative Materials Corp
$ 0,11
(4,76%)
3,27M
CVGRCity View Green Holdings Inc
$ 0,01
(33,33%)
2,35M
CATCAT Strategic Metals Corporation
$ 0,005
(0,00%)
2,33M
PREVPreveCeutical Medical Inc
$ 0,035
(16,67%)
1,71M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock